News Room
News Room
News Room
First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy
Study opens pathway to investigational therapy for patients with Tourette syndrome who have exhausted approved treatments CHICAGO — March 9, 2026 — Emalex [...]
Biotech Innovation Update
Last year, Paragon Biosciences and its portfolio companies advanced transformative science with a singular mission: to accelerate breakthroughs that improve lives. Across [...]
Groundbreaking Achievements and Pivotal Milestones for Paragon and its Portfolio Companies
In 2024, Paragon and its portfolio companies achieved remarkable research and development progress, driving innovative solutions for patients with critical unmet needs. [...]
Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
Topline data from Phase 3 study in patients with Tourette syndrome shows statistical significance between ecopipam and placebo for both the primary efficacy endpoint [...]
Emalex Biosciences Named “Neuroscience Therapeutics Company Of The Year” by BioTech Breakthrough
Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industries CHICAGO, November 19, 2024 – Emalex Biosciences was named “Neuroscience [...]
Article Highlights Positive Study Results Presented at AAN Annual Meeting
By Mary Beth Nierengarten, April 1, 2024 – Ecopipam reduced the number of tics and the level of daily interference they cause in children [...]
